Home

Christopher Lewis Stone

CIK 1453373 · VP, Gen. Counsel & Secretary · last filed 2020-12-17

Christopher Lewis Stone is a VP, Gen. Counsel & Secretary who has filed 21 SEC Form 4 insider transactions across 1 company since 2009. The most recent filing shows the insider sold $512.0K of PDLI on Dec 17, 2020. Across all open-market trades the lifetime net is −$512.0K, making them a net seller over the disclosed history. 23 SEC filings were submitted jointly with PDL BIOPHARMA, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

21

Lifetime Open-Market Net

-$512.0K

Filer Profile

Reported Address
932 SOUTHWOOD BLVD.
INCLINE VILLAGE, NV 89451
Related Filers
PDL BIOPHARMA, INC. — 23 joint filings, latest 2020-12-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PDL BIOPHARMA, INC. (PDLI) Delisted VP, Gen. Counsel & Secretary 405,559 — — -$512.0K 21 2020-12-17

Recent Filings

21 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-12-17 PDL BIOPHARMA, INC. (PDLI) Delisted Sell (S) −200,000 -$512.0K EDGAR
2020-12-04 PDL BIOPHARMA, INC. (PDLI) Delisted Disp (D) −11,544 $0 EDGAR
2020-04-07 PDL BIOPHARMA, INC. (PDLI) Delisted Grant (A) +422,078 $0 EDGAR
2020-04-07 PDL BIOPHARMA, INC. (PDLI) Delisted Tax (F) −3,926 -$13.2K EDGAR
2020-01-10 PDL BIOPHARMA, INC. (PDLI) Delisted Grant (A) +422,078 $0 EDGAR
2019-04-16 PDL BIOPHARMA, INC. (PDLI) Delisted Grant (A) — $0 EDGAR
2019-04-01 PDL BIOPHARMA, INC. (PDLI) Delisted Grant (A) — $0 EDGAR
2018-12-28 PDL BIOPHARMA, INC. (PDLI) Delisted Mixed −231,836 -$10.8K EDGAR
2018-09-27 PDL BIOPHARMA, INC. (PDLI) Delisted Grant (A) — $0 EDGAR
2018-06-12 PDL BIOPHARMA, INC. (PDLI) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 21
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.